Dr. Nataliya Mar, MD
NPI: 1922240191
Total Payments
$111,687
2024 Payments
$33,128
Companies
15
Transactions
147
Medicare Patients
1,060
Medicare Billing
$511,757
Payment Breakdown by Category
Other$82,517 (73.9%)
Consulting$14,691 (13.2%)
Food & Beverage$5,237 (4.7%)
Travel$4,886 (4.4%)
Research$4,256 (3.8%)
Education$99.95 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $65,665 | 34 | 58.8% |
| Consulting Fee | $14,691 | 11 | 13.2% |
| Honoraria | $9,456 | 4 | 8.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,158 | 5 | 6.4% |
| Food and Beverage | $5,237 | 68 | 4.7% |
| Travel and Lodging | $4,886 | 14 | 4.4% |
| Unspecified | $4,256 | 3 | 3.8% |
| Entertainment | $238.76 | 2 | 0.2% |
| Education | $99.95 | 6 | 0.1% |
Payments by Type
General
$107,431
144 transactions
Research
$4,256
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $34,281 | 42 | $0 (2024) |
| Merck Sharp & Dohme LLC | $28,034 | 24 | $0 (2024) |
| Seagen Inc. | $21,639 | 27 | $0 (2023) |
| Astellas Pharma US Inc | $12,337 | 11 | $0 (2023) |
| Aveo Pharmaceuticals, Inc. | $4,864 | 12 | $0 (2024) |
| Exelixis Inc. | $4,684 | 8 | $0 (2024) |
| PFIZER INC. | $4,420 | 9 | $0 (2024) |
| Foundation Medicine, Inc. | $600.00 | 2 | $0 (2019) |
| Gilead Sciences, Inc. | $440.58 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $121.87 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $33,128 | 41 | Merck Sharp & Dohme LLC ($18,577) |
| 2023 | $34,908 | 40 | Eisai Inc. ($16,715) |
| 2022 | $20,379 | 33 | EISAI INC. ($10,063) |
| 2021 | $7,125 | 8 | Seagen Inc. ($4,956) |
| 2020 | $15,306 | 21 | Seagen Inc. ($9,900) |
| 2019 | $841.53 | 4 | Foundation Medicine, Inc. ($600.00) |
All Payment Transactions
147 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | PADCEV (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: PADCEV CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 12/05/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $1,980.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/25/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), BALVERSA | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: Oncology | ||||||
| 11/23/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $33.53 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $105.43 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $656.21 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,962.50 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $785.00 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $120.26 | General |
| Category: Oncology | ||||||
| 09/13/2024 | PFIZER INC. | PADCEV (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: PADCEV CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 09/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $75.00 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: Oncology | ||||||
| 08/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 08/07/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2024 | Eisai Inc. | — | Food and Beverage | In-kind items and services | $67.99 | General |
| 07/31/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 07/03/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), BALVERSA | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $124.88 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $96.02 | General |
| Category: ONC | ||||||
| 06/02/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $60.34 | General |
| Category: Oncology | ||||||
| 06/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $174.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 06/01/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $95.34 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PADCEV CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,140 | 2 |
| PCYC-1128-CA | Pharmacyclics LLC, An AbbVie Company | $116.10 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 265 | 1,085 | $691,338 | $127,519 |
| 2022 | 3 | 261 | 1,150 | $731,978 | $136,470 |
| 2021 | 3 | 267 | 1,263 | $671,995 | $153,752 |
| 2020 | 5 | 267 | 989 | $459,453 | $94,016 |
Total Patients
1,060
Total Services
4,487
Medicare Billing
$511,757
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 187 | 987 | $624,771 | $115,532 | 18.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $22,316 | $4,275 | 19.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 21 | $18,522 | $3,123 | 16.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 22 | $14,092 | $2,339 | 16.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 12 | 27 | $11,637 | $2,250 | 19.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 176 | 1,027 | $650,091 | $121,383 | 18.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 46 | $36,256 | $6,419 | 17.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 34 | 34 | $27,098 | $5,314 | 19.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 26 | 43 | $18,533 | $3,354 | 18.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 151 | 1,089 | $590,553 | $134,555 | 22.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 60 | 103 | $28,031 | $8,010 | 28.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 38 | 38 | $29,026 | $6,124 | 21.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 18 | 33 | $24,385 | $5,063 | 20.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 130 | 770 | $373,422 | $73,317 | 19.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 65 | 135 | $27,691 | $9,410 | 34.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 37 | 37 | $27,158 | $5,029 | 18.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 23 | 23 | $20,286 | $4,074 | 20.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 24 | $10,896 | $2,186 | 20.1% |
About Dr. Nataliya Mar, MD
Dr. Nataliya Mar, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/02/2009. The National Provider Identifier (NPI) number assigned to this provider is 1922240191.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nataliya Mar, MD has received a total of $111,687 in payments from pharmaceutical and medical device companies, with $33,128 received in 2024. These payments were reported across 147 transactions from 15 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($65,665).
As a Medicare-enrolled provider, Mar has provided services to 1,060 Medicare beneficiaries, totaling 4,487 services with total Medicare billing of $511,757. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location Orange, CA
- Active Since 04/02/2009
- Last Updated 05/08/2018
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1922240191
Products in Payments
- Lenvima (Drug) $33,859
- PADCEV (Biological) $25,520
- KEYTRUDA (Biological) $14,078
- LYNPARZA (Biological) $13,828
- PADCEV (Drug) $6,300
- Padcev (Drug) $6,037
- FOTIVDA (Drug) $4,864
- CABOMETYX (Drug) $2,516
- Cabometyx (Drug) $2,168
- FOUNDATIONONE LIQUID (Device) $600.00
- Trodelvy (Drug) $315.58
- INLYTA (Drug) $205.61
- LYNPARZA (Drug) $121.87
- Imbruvica (Drug) $116.10
- ERLEADA (Drug) $97.06
- Rubraca (Drug) $28.07
- Bavencio (Drug) $25.52
- XTANDI (Drug) $13.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Orange
Dr. Bhavraj Khalsa, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $350,385
Student in an Organized Health Care Education/Training Program $350,385
Dr. Adachukwu Ezenekwe, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $301,130
Student in an Organized Health Care Education/Training Program $301,130
Dr. Sandra Sunhee Park, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $77,359
Student in an Organized Health Care Education/Training Program $77,359
Mr. Travis Scudday, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $59,102
Student in an Organized Health Care Education/Training Program $59,102
Piotr Sowa, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $50,493
Student in an Organized Health Care Education/Training Program $50,493
Dr. Joffre Olaya
Student in an Organized Health Care Education/Training Program — Payments: $13,771
Student in an Organized Health Care Education/Training Program $13,771